A Phase 2 Trial of the Effect of Antiandrogen Therapy on COVID-19 Outcome: No Evidence of Benefit, Supported by Epidemiology and In Vitro Data
Clinical Trial
[키워드] 95% CI
95% confidence interval
Acetate
affected
Air-liquid interface
androgen
Androgen deprivation therapy
antiandrogen
Bicalutamide
clinical study
clinical trial
clinically
Combination
conducted
confounders
COVID-19
COVID-19 symptoms
Culture
death
Deprivation
discharge
Effect
enrolled
enzalutamide
epidemiological
Epidemiological study
epidemiologically
evaluate the effect
Evidence
evidence of
hazard ratio
higher risk
hospital
Hospitalization
hospitalized COVID-19 patient
immune response
include
intensive care
investigated
limitation
lung cells
mechanical ventilation
Patient
patients treated
Phase 2
Primary outcome
Prostate cancer
Randomized
randomized trial
required
Research
Result
Retrospective study
risk
SARS-CoV-2
SARS-COV-2 infection
Standard of care
Support
Testosterone
therapeutic effect
therapy
Treatment
Trial
virus replication
[DOI] 10.1016/j.eururo.2021.12.013 PMC 바로가기 [Article Type] Clinical Trial
[DOI] 10.1016/j.eururo.2021.12.013 PMC 바로가기 [Article Type] Clinical Trial